Casey Johnson1, Matthew Hohenboken2, Terry Poling3, Peter Jaehnig4, Niranjan Kanesa-Thasan2. 1. Johnson County Clin-Trials LLC, Lenexa, Kansas. 2. Novartis Vaccines and Diagnostics, Inc, Cambridge, Massachusetts. 3. Heartland Research Associates LLC, Wichita, Kansas. 4. Novartis Vaccines and Diagnostics, GmbH, Marburg, Germany.
Abstract
BACKGROUND: A/H3N2 variant (H3N2v) influenza may sustain human-to-human transmission, and an available candidate vaccine would be important. METHODS: In this phase I, randomized, observer-blind, dose-ranging study, 627 healthy subjects ≥ 3 years of age were randomized to receive 2 vaccinations with H3N2c cell-culture-derived vaccine doses containing 3.75 µg, 7.5 µg, or 15 µg hemagglutinin antigen of H3N2v with or without MF59 (registered trademark of Novartis AG) adjuvant (an oil-in-water emulsion). This paper reports Day 43 planned interim data. RESULTS: Single MF59-adjuvanted H3N2c doses elicited immune responses in almost all subjects regardless of antigen and adjuvant dose; the Center for Biologics Evaluation Research and Review (CBER) licensure criteria were met for all groups. Subjects with prevaccination hemagglutination inhibition titers <10 and children 3-<9 years achieve CBER criteria only after receiving 2 doses of nonadjuvanted H3N2c vaccine. Highest antibody titers were observed in the 7.5 µg + 0.25 mL MF59 groups in all age cohorts. MF59-adjuvanted H3N2c vaccines showed the highest rates of solicited local and systemic events, predominately mild or moderate. CONCLUSIONS: A single dose of H3N2c vaccine may be immunogenic and supports further development of MF59-adjuvanted H3N2c vaccines, especially for pediatric populations. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT01855945 (http://clinicaltrials.gov/ct2/show/NCT01855945).
RCT Entities:
BACKGROUND: A/H3N2 variant (H3N2v) influenza may sustain human-to-human transmission, and an available candidate vaccine would be important. METHODS: In this phase I, randomized, observer-blind, dose-ranging study, 627 healthy subjects ≥ 3 years of age were randomized to receive 2 vaccinations with H3N2c cell-culture-derived vaccine doses containing 3.75 µg, 7.5 µg, or 15 µg hemagglutinin antigen of H3N2v with or without MF59 (registered trademark of Novartis AG) adjuvant (an oil-in-water emulsion). This paper reports Day 43 planned interim data. RESULTS: Single MF59-adjuvanted H3N2c doses elicited immune responses in almost all subjects regardless of antigen and adjuvant dose; the Center for Biologics Evaluation Research and Review (CBER) licensure criteria were met for all groups. Subjects with prevaccination hemagglutination inhibition titers <10 and children 3-<9 years achieve CBER criteria only after receiving 2 doses of nonadjuvanted H3N2c vaccine. Highest antibody titers were observed in the 7.5 µg + 0.25 mL MF59 groups in all age cohorts. MF59-adjuvanted H3N2c vaccines showed the highest rates of solicited local and systemic events, predominately mild or moderate. CONCLUSIONS: A single dose of H3N2c vaccine may be immunogenic and supports further development of MF59-adjuvanted H3N2c vaccines, especially for pediatric populations. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT01855945 (http://clinicaltrials.gov/ct2/show/NCT01855945).
Authors: Christoph Hatz; Frank von Sonnenburg; Daniela Casula; Maria Lattanzi; Geert Leroux-Roels Journal: Vaccine Date: 2012-03-22 Impact factor: 3.641
Authors: Wendy Keitel; Nicola Groth; Maria Lattanzi; Michaela Praus; Anne Katrin Hilbert; Astrid Borkowski; Ted F Tsai Journal: Vaccine Date: 2009-10-14 Impact factor: 3.641
Authors: Danuta M Skowronski; Naveed Z Janjua; Gaston De Serres; Dale Purych; Vladimir Gilca; David W Scheifele; Marc Dionne; Suzana Sabaiduc; Jennifer L Gardy; Guiyun Li; Nathalie Bastien; Martin Petric; Guy Boivin; Yan Li Journal: J Infect Dis Date: 2012-08-07 Impact factor: 5.226
Authors: Lamberto Manzoli; John P A Ioannidis; Maria Elena Flacco; Corrado De Vito; Paolo Villari Journal: Hum Vaccin Immunother Date: 2012-07-01 Impact factor: 3.452
Authors: Iain Stephenson; Karl G Nicholson; John M Wood; Maria C Zambon; Jacqueline M Katz Journal: Lancet Infect Dis Date: 2004-08 Impact factor: 25.071
Authors: Xiaoquan Wang; Natalia A Ilyushina; Vladimir Y Lugovtsev; Nicolai V Bovin; Laura K Couzens; Jin Gao; Raymond P Donnelly; Maryna C Eichelberger; Hongquan Wan Journal: J Virol Date: 2017-01-03 Impact factor: 5.103